Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

SELL
$0.34 - $0.56 $472 - $778
-1,390 Reduced 0.66%
208,320 $81,000
Q4 2022

Feb 13, 2023

SELL
$0.36 - $1.26 $169 - $592
-470 Reduced 0.22%
209,710 $100,000
Q3 2022

Nov 14, 2022

BUY
$1.75 - $2.88 $186,784 - $307,393
106,734 Added 103.18%
210,180 $351,000
Q2 2022

Aug 12, 2022

SELL
$1.91 - $5.11 $108,829 - $291,162
-56,979 Reduced 35.52%
103,446 $293,000
Q1 2022

May 13, 2022

BUY
$5.02 - $10.47 $46,500 - $96,983
9,263 Added 6.13%
160,425 $806,000
Q4 2021

Feb 11, 2022

SELL
$8.95 - $16.88 $21,363 - $40,292
-2,387 Reduced 1.55%
151,162 $1.51 Million
Q3 2021

Nov 12, 2021

BUY
$12.2 - $16.75 $158,941 - $218,219
13,028 Added 9.27%
153,549 $2 Million
Q2 2021

Aug 13, 2021

BUY
$12.03 - $17.51 $1.69 Million - $2.46 Million
140,521 New
140,521 $1.98 Million

About Finch Therapeutics Group, Inc.


  • Ticker FNCH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 47,688,400
  • Market Cap $63.4M
  • Description
  • Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides diffi...
More about FNCH
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.